Skip to Content

Carbaglu Approval History

  • FDA approved: Yes (First approved March 18th, 2010)
  • Brand name: Carbaglu
  • Generic name: carglumic acid
  • Dosage form: Tablets
  • Company: Orphan Europe
  • Treatment for: Hyperammonemia

Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).

Development History and FDA Approval Process for Carbaglu

Mar 18, 2010Approval FDA Approves Carbaglu to Treat Condition That Causes Elevated Ammonia Levels

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.